ClinicalTrials.gg
CompletedNCT00633893Updated Nov 25, 2013Results posted

Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

A Phase 3 interventional study of Apixaban and Placebo in Venous Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 429 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-25.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,711
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing apixaban in Venous Thrombosis — 5 open to participants now, 6 under way, 1 of them phase 3. apixaban · Venous Thrombosis.

Enrollment
6th of 26
2,711 · median 445
Started
2008
with 1 other
Phase 3
10 of 26
1 open now
Registered
5th of 26
by date
Lead sponsor
6 of 26
Bristol-Myers Squibb

Among the 26 studies testing apixaban in Venous Thrombosis, this one is the 6th largest by enrollment, is one of 2 that started in 2008, is one of 10 in phase 3, and was the 5th registered.

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

Browse Venous Thrombosis studies →

Open to participants now

5 of the 26 studies testing apixaban in Venous Thrombosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 84 Venous Thrombosis studies recruiting now, 59 (70%) set no upper age limit and 9 (11%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing apixaban in Venous Thrombosis, or all of them as a file.
02

Study summary

The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)

03

Conditions studied

  • Venous Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥ 18 years of age;
  • Clinical diagnosis of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE);
  • Anticoagulant treatment completed
  • No recurrence of Venous Thromboembolism (VTE)

Exclusion criteria

Exclusion Criteria:

  • Subjects with indications for long-term treatment with a vitamin K antagonist
  • Active bleeding or high risk for serious bleeding
  • Short
  • Uncontrolled high blood pressure
  • Impaired kidney or liver function
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
2,711 participants (actual)

Study arms

  • Experimental
    1

    2.5 mg

    Drug: Apixaban

  • Experimental
    2

    5.0 mg

    Drug: Apixaban

  • Active comparator
    3

    0 mg

    Drug: Placebo

Interventions

  • Tablets, Oral, twice daily, 12 months

    Also known as: BMS-562247

  • DrugPlacebo

    Tablets, Oral, twice daily, 12 months

06

What researchers measure

Primary outcomes

  1. Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation

    VTE included: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. For missing endpoint data, participants were imputed as having had a primary efficacy outcome event.

    Time frame: Day 1 up to 12 Months

  2. Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation

    VTE included: nonfatal DVT or nonfatal PE. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted. Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits.

    Time frame: Day 1 up to 12 months

Secondary outcomes

  1. Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or VTE-related Death During the Intended Treatment Period - Randomized Population With Imputation

    VTE includes nonfatal DVT or nonfatal PE. All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. For missing endpoint data, participants were imputed as having had a primary efficacy outcome event.

    Time frame: Day 1 up to 12 Months

  2. Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) -Related Death During the Intended Treatment Period - Randomized Population With Imputation

    VTE includes nonfatal DVT or nonfatal PE. All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Composite endpoint included events that occurred any time from randomization until end of the intended treatment period, regardless of whether the participants were receiving drug treatment. Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. If there were missing endpoint data, participants were imputed as having had an efficacy outcome event.

    Time frame: Day 1 up to 12 Months

  3. Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population With Imputation

    DVT was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and assessed by compression ultrasound and/or venography. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits.

    Time frame: Day 1 up to 12 Months

  4. Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population With Imputation

    PE was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.

    Time frame: Day 1 up to 12 Months

  5. Adjudicated Venous Thromboembolism (VTE) - Related Death During the Intended Treatment Period - Randomized Population With Imputation

    VTE-related death defined as: PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Participants with missing endpoint information were classified as having had the efficacy event (imputation).

    Time frame: Day 1 up to 12 Months

  6. Adjudicated Cardiovascular (CV)-Related Death During the Intended Treatment Period - Randomized Population With Imputation

    CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event and were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.

    Time frame: Day 1 up to 12 Months

  7. Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation

    DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.

    Time frame: Day 1 up to 12 Months

  8. Number of Participants With an Adjudicated Symptomatic Nonfatal Venous Thromboembolism (VTE) Recurrence or Death (All Cause) During the Intended Treatment Period - Randomized Participants Without Imputation

    All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. First event category was the first primary event for each participant and each participant was counted once. CV-related death was presented excluding VTE-related death. In participants with event category, each participant was counted once in each event category but could have been counted in multiple categories. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted.

    Time frame: Day 1 up to 12 Months

  9. Adjudicated Major Bleeding During the Treatment Period - Treated Population

    Major bleeding was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or another critical organ; or is fatal. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Confidence interval (CI) for event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.

    Time frame: Day 1 up to 12 Months

  10. Adjudicated Composite of Major/Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants

    Major bleeding and clinically relevant non-major bleeding were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Major bleeding was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or another critical organ or is fatal. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.

    Time frame: Day 1 up to 12 Months

  11. Adjudicated Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants

    Non-major clinically relevant bleeding was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and defined as: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding (or lasting more than 5 minutes); spontaneous hematuria (macroscopic or lasted more than 24 hours after instrumentation of the urogenital tract); macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis (if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits.

    Time frame: Day 1 up to 12 months

  12. Adjudicated Clinically Relevant Minor Bleeding During the Treatment Period - Treated Participants

    All bleeding events were reviewed by the central independent adjudication committee blinded to treatment and classified as major bleeding, clinically relevant non-major bleeding, minor bleeding or no bleeding. If event was not major or clinically relevant non-major, it was judged to be minor. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.

    Time frame: Day 1 up to 12 months

  13. Adjudicated Total Bleeding During the Treatment Period - Treated Participants

    All bleeding events were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Total bleeding was defined as any major, clinically relevant non-major, or minor bleeding. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.

    Time frame: Day 1 up to 12 months

  14. Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Venous Thromboembolism-related Death During the Intended Treatment Period - Randomized Population Without Imputation

    VTE related death defined as PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE and death, were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints.

    Time frame: Day 1 up to 12 Months

  15. Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) - Related Death During the Intended Treatment Period - Randomized Population Without Imputation

    CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event. Index events of DVT and/or PE, along with myocardial infarction and stroke were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted.

    Time frame: Day 1 up to 12 Months

  16. Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population Without Imputation

    DVT was adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.

    Time frame: Day 1 up to 12 Months

  17. Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population Without Imputation

    PE was adjudicated/confirmed by a central independent adjudication committee blinded to treatment: PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.

    Time frame: Day 1 up to 12 Months

  18. Adjudicated Venous Thromboembolism (VTE)- Related Death During the Intended Treatment Period - Randomized Population Without Imputation

    VTE related death defined as PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, and death, were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint.

    Time frame: Day 1 up to 12 Months

  19. Adjudicated Cardio Vascular (CV)-Related Death During the Intended Treatment Period - Randomized Population Without Imputation

    CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event and these were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.

    Time frame: Day 1 up to 12 Months

  20. Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation

    DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.

    Time frame: Day 1 up to 12 Months

07

Results

Posted Oct 25, 2013

Participant flow

First participant, first visit: 16 May 2008; Last participant, last visit: 24 August 2012.

Participant flow — Overall Study
MilestoneApixaban 2.5 mgApixaban 5 mgPlacebo
Started840813829
Completed726684641
Not completed114129188
Withdrew: Death139
Withdrew: Adverse event6558126
Withdrew: Withdrawal by subject7126
Withdrew: Lost to follow-up248
Withdrew: Poor/non-compliance5123
Withdrew: Pregnancy211
Withdrew: Not meet/no longer meets criteria464
Withdrew: Other283331

Outcome measures

PrimaryAdjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation

VTE included: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. For missing endpoint data, participants were imputed as having had a primary efficacy outcome event.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · Proportion of participants
Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation
Proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation0.0381 (0.0252 to 0.0510)0.0418 (0.0281 to 0.0556)0.1158 (0.0940 to 0.1376)
Statistical analysis
  • Apixaban 2.5 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.3283 · 95% CI 0.2225 to 0.4844
  • Apixaban 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.3615 · 95% CI 0.2475 to 0.5281
SecondaryAdjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or VTE-related Death During the Intended Treatment Period - Randomized Population With Imputation

VTE includes nonfatal DVT or nonfatal PE. All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. For missing endpoint data, participants were imputed as having had a primary efficacy outcome event.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · Proportion of participants
Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or VTE-related Death During the Intended Treatment Period - Randomized Population With Imputation
Proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or VTE-related Death During the Intended Treatment Period - Randomized Population With Imputation0.0321 (0.0202 to 0.0441)0.0418 (0.0281 to 0.0556)0.1110 (0.0896 to 0.1324)
Statistical analysis
  • Apixaban 2.5 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.2891 · 95% CI 0.1902 to 0.4395
  • Apixaban 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.3774 · 95% CI 0.2577 to 0.5525
PrimaryAdjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation

VTE included: nonfatal DVT or nonfatal PE. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted. Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits.

Time frame:
Day 1 up to 12 months
Reported as:
Number · Proportion of participants
Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation
Proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation0.0226 (0.0126 to 0.0327)0.0172 (0.0083 to 0.0262)0.0929 (0.0731 to 0.1126)
Statistical analysis
  • Apixaban 2.5 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.2422 · 95% CI 0.1476 to 0.3975
  • Apixaban 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.1861 · 95% CI 0.1062 to 0.3261
SecondaryAdjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) -Related Death During the Intended Treatment Period - Randomized Population With Imputation

VTE includes nonfatal DVT or nonfatal PE. All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Composite endpoint included events that occurred any time from randomization until end of the intended treatment period, regardless of whether the participants were receiving drug treatment. Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. If there were missing endpoint data, participants were imputed as having had an efficacy outcome event.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · proportion of participants
Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) -Related Death During the Intended Treatment Period - Randomized Population With Imputation
proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) -Related Death During the Intended Treatment Period - Randomized Population With Imputation0.0321 (0.0202 to 0.0441)0.0418 (0.0281 to 0.0556)0.1146 (0.0929 to 0.1363)
Statistical analysis
  • Apixaban 2.5 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.2799 · 95% CI 0.1844 to 0.4247
  • Apixaban 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.3653 · 95% CI 0.2500 to 0.5338
SecondaryAdjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population With Imputation

DVT was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and assessed by compression ultrasound and/or venography. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · Proportion of participants
Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population With Imputation
Proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population With Imputation0.0226 (0.0126 to 0.0327)0.0344 (0.0219 to 0.0470)0.0869 (0.0677 to 0.1060)
Statistical analysis
  • Apixaban 2.5 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.2615 · 95% CI 0.1593 to 0.4292
  • Apixaban 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.3972 · 95% CI 0.2595 to 0.6079
SecondaryAdjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population With Imputation

PE was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · Proportion of participants
Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population With Imputation
Proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population With Imputation0.0274 (0.0163 to 0.0384)0.0308 (0.0189 to 0.0426)0.0446 (0.0306 to 0.0587)
Statistical analysis
  • Apixaban 2.5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1084 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.6087 · 95% CI 0.3653 to 1.0145
  • Apixaban 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1329 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.6846 · 95% CI 0.4164 to 1.1257
SecondaryAdjudicated Venous Thromboembolism (VTE) - Related Death During the Intended Treatment Period - Randomized Population With Imputation

VTE-related death defined as: PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Participants with missing endpoint information were classified as having had the efficacy event (imputation).

Time frame:
Day 1 up to 12 Months
Reported as:
Number · Proportion of participants
Adjudicated Venous Thromboembolism (VTE) - Related Death During the Intended Treatment Period - Randomized Population With Imputation
Proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Venous Thromboembolism (VTE) - Related Death During the Intended Treatment Period - Randomized Population With Imputation0.0202 (0.0107 to 0.0298)0.0295 (0.0179 to 0.0412)0.0314 (0.0195 to 0.0432)
Statistical analysis
  • Apixaban 2.5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3059 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.6470 · 95% CI 0.3543 to 1.1813
  • Apixaban 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.8288 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.9416 · 95% CI 0.5458 to 1.6245
SecondaryAdjudicated Cardiovascular (CV)-Related Death During the Intended Treatment Period - Randomized Population With Imputation

CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event and were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · Proportion of Participants
Adjudicated Cardiovascular (CV)-Related Death During the Intended Treatment Period - Randomized Population With Imputation
Proportion of ParticipantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Cardiovascular (CV)-Related Death During the Intended Treatment Period - Randomized Population With Imputation0.0202 (0.0107 to 0.0298)0.0295 (0.0179 to 0.0412)0.0350 (0.0225 to 0.0475)
Statistical analysis
  • Apixaban 2.5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1316 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.5794 · 95% CI 0.3215 to 1.0443
  • Apixaban 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.5288 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.8433 · 95% CI 0.4959 to 1.4341
SecondaryAdjudicated All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation

DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · Proportion of participants
Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation
Proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation0.0262 (0.0154 to 0.0370)0.0308 (0.0189 to 0.0426)0.0398 (0.0265 to 0.0531)
Statistical analysis
  • Apixaban 2.5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.2361 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.6577 · 95% CI 0.3874 to 1.1169
  • Apixaban 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3155 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.7708 · 95% CI 0.4631 to 1.2832
SecondaryNumber of Participants With an Adjudicated Symptomatic Nonfatal Venous Thromboembolism (VTE) Recurrence or Death (All Cause) During the Intended Treatment Period - Randomized Participants Without Imputation

All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. First event category was the first primary event for each participant and each participant was counted once. CV-related death was presented excluding VTE-related death. In participants with event category, each participant was counted once in each event category but could have been counted in multiple categories. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · participants
Number of Participants With an Adjudicated Symptomatic Nonfatal Venous Thromboembolism (VTE) Recurrence or Death (All Cause) During the Intended Treatment Period - Randomized Participants Without Imputation
participantsApixaban 2.5 mgApixaban 5 mgPlacebo
First event: Participants with nonfatal DVT6753
First event: Participants with nonfatal PE7413
First event: All-Cause Death6311
CV-related Death (included in all-cause total)003
VTE-related Death (included in all-cause total)237
Participants with event: nonfatal DVT6853
Participants with event: nonfatal PE8415
Participants with event: All cause death7414
SecondaryAdjudicated Major Bleeding During the Treatment Period - Treated Population

Major bleeding was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or another critical organ; or is fatal. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Confidence interval (CI) for event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · Proportion of participants
Adjudicated Major Bleeding During the Treatment Period - Treated Population
Proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Major Bleeding During the Treatment Period - Treated Population0.0024 (0.0000 to 0.0057)0.0012 (0.0000 to 0.0036)0.0048 (0.0001 to 0.0096)
Statistical analysis
  • Apixaban 2.5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3925 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.4850 · 95% CI 0.0891 to 2.6391
  • Apixaban 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3551 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 0.2457 · 95% CI 0.0269 to 2.2437
SecondaryAdjudicated Composite of Major/Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants

Major bleeding and clinically relevant non-major bleeding were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Major bleeding was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or another critical organ or is fatal. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · proportion of participants
Adjudicated Composite of Major/Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants
proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Composite of Major/Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants0.0321 (0.0202 to 0.0441)0.0432 (0.0292 to 0.0571)0.0266 (0.0157 to 0.0376)
Statistical analysis
  • Apixaban 2.5 mg · Cochran-Mantel-Haenszel · p = 0.5148 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 1.2027 · 95% CI 0.6897 to 2.0975
  • Apixaban 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1412 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 1.6160 · 95% CI 0.9554 to 2.7336
SecondaryAdjudicated Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants

Non-major clinically relevant bleeding was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and defined as: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding (or lasting more than 5 minutes); spontaneous hematuria (macroscopic or lasted more than 24 hours after instrumentation of the urogenital tract); macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis (if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits.

Time frame:
Day 1 up to 12 months
Reported as:
Number · Proportion of participants
Adjudicated Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants
Proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants0.0298 (0.0183 to 0.0413)0.0419 (0.0281 to 0.0557)0.0230 (0.0128 to 0.0332)
Statistical analysis
  • Apixaban 2.5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3932 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 1.2928 · 95% CI 0.7158 to 2.3348
  • Apixaban 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0621 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 1.8235 · 95% CI 1.0470 to 3.1760
SecondaryAdjudicated Clinically Relevant Minor Bleeding During the Treatment Period - Treated Participants

All bleeding events were reviewed by the central independent adjudication committee blinded to treatment and classified as major bleeding, clinically relevant non-major bleeding, minor bleeding or no bleeding. If event was not major or clinically relevant non-major, it was judged to be minor. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.

Time frame:
Day 1 up to 12 months
Reported as:
Number · Proportion of participants
Adjudicated Clinically Relevant Minor Bleeding During the Treatment Period - Treated Participants
Proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Clinically Relevant Minor Bleeding During the Treatment Period - Treated Participants0.0893 (0.0700 to 0.1086)0.1208 (0.0984 to 0.1433)0.0702 (0.0528 to 0.0876)
Statistical analysis
  • Apixaban 2.5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1691 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 1.2579 · 95% CI 0.9064 to 1.7457
  • Apixaban 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0013 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 1.6971 · 95% CI 1.2468 to 2.3102
SecondaryAdjudicated Total Bleeding During the Treatment Period - Treated Participants

All bleeding events were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Total bleeding was defined as any major, clinically relevant non-major, or minor bleeding. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.

Time frame:
Day 1 up to 12 months
Reported as:
Number · Proportion of participants
Adjudicated Total Bleeding During the Treatment Period - Treated Participants
Proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Total Bleeding During the Treatment Period - Treated Participants0.1119 (0.0906 to 0.1332)0.1492 (0.1247 to 0.1737)0.0896 (0.0701 to 0.1091)
Statistical analysis
  • Apixaban 2.5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.1466 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 1.2374 · 95% CI 0.9276 to 1.6507
  • Apixaban 5 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.0005 (Hochberg adjusted p-value for superiority based on 2 hypotheses tests for apixaban 2.5mg group comparing with placebo group and for apixaban 5mg group comparing with placebo group.) · Risk ratio (rr): 1.6468 · 95% CI 1.2552 to 2.1606
SecondaryAdjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Venous Thromboembolism-related Death During the Intended Treatment Period - Randomized Population Without Imputation

VTE related death defined as PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE and death, were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · proportion of participants
Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Venous Thromboembolism-related Death During the Intended Treatment Period - Randomized Population Without Imputation
proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Venous Thromboembolism-related Death During the Intended Treatment Period - Randomized Population Without Imputation0.0167 (0.0080 to 0.0253)0.0172 (0.0083 to 0.0262)0.0881 (0.0688 to 0.1073)
SecondaryAdjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) - Related Death During the Intended Treatment Period - Randomized Population Without Imputation

CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event. Index events of DVT and/or PE, along with myocardial infarction and stroke were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · proportion of participants
Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) - Related Death During the Intended Treatment Period - Randomized Population Without Imputation
proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) - Related Death During the Intended Treatment Period - Randomized Population Without Imputation0.0167 (0.0080 to 0.0253)0.0172 (0.0083 to 0.0262)0.0917 (0.0720 to 0.1113)
SecondaryAdjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population Without Imputation

DVT was adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · proportion of participants
Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population Without Imputation
proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population Without Imputation0.0071 (0.0014 to 0.0128)0.0098 (0.0031 to 0.0166)0.0639 (0.0473 to 0.0806)
SecondaryAdjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population Without Imputation

PE was adjudicated/confirmed by a central independent adjudication committee blinded to treatment: PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · Proportion of participants
Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population Without Imputation
Proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population Without Imputation0.0095 (0.0030 to 0.0161)0.0049 (0.0001 to 0.0097)0.0181 (0.0090 to 0.0272)
SecondaryAdjudicated Venous Thromboembolism (VTE)- Related Death During the Intended Treatment Period - Randomized Population Without Imputation

VTE related death defined as PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, and death, were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · Proportion of participants
Adjudicated Venous Thromboembolism (VTE)- Related Death During the Intended Treatment Period - Randomized Population Without Imputation
Proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Venous Thromboembolism (VTE)- Related Death During the Intended Treatment Period - Randomized Population Without Imputation0.0024 (0.0000 to 0.0057)0.0037 (0.0000 to 0.0079)0.0084 (0.0022 to 0.0147)
SecondaryAdjudicated Cardio Vascular (CV)-Related Death During the Intended Treatment Period - Randomized Population Without Imputation

CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event and these were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · Proportion of participants
Adjudicated Cardio Vascular (CV)-Related Death During the Intended Treatment Period - Randomized Population Without Imputation
Proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated Cardio Vascular (CV)-Related Death During the Intended Treatment Period - Randomized Population Without Imputation0.0024 (0.0000 to 0.0057)0.0037 (0.0000 to 0.0079)0.0121 (0.0046 to 0.0195)
SecondaryAdjudicated All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation

DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.

Time frame:
Day 1 up to 12 Months
Reported as:
Number · Proportion of participants
Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation
Proportion of participantsApixaban 2.5 mgApixaban 5 mgPlacebo
Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation0.0083 (0.0022 to 0.0145)0.0049 (0.0001 to 0.0097)0.0169 (0.0081 to 0.0257)

Adverse events

Collected over Day 1 up to 12 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Apixaban 2.5mg—112/840 (13.3%)341/840 (40.6%)
Apixaban 5mg—107/811 (13.2%)305/811 (37.6%)
Placebo—158/826 (19.1%)318/826 (38.5%)
Most frequent serious events
Showing 10 of 259
Most frequent serious events
EventApixaban 2.5mgApixaban 5mgPlacebo
DEEP VEIN THROMBOSISVascular disorders3/8409/81140/826
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders5/8403/81120/826
PNEUMONIAInfections and infestations5/8403/8111/826
PREGNANCYPregnancy, puerperium and perinatal conditions3/8404/8111/826
ATRIAL FIBRILLATIONCardiac disorders2/8401/8114/826
ANAEMIABlood and lymphatic system disorders0/8403/8112/826
MYOCARDIAL INFARCTIONCardiac disorders1/8403/8112/826
RESPIRATORY TRACT INFECTIONInfections and infestations0/8403/8111/826
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders3/8403/8112/826
MYOCARDIAL ISCHAEMIACardiac disorders0/8401/8113/826
Most frequent other events
Showing 10 of 23
Most frequent other events
EventApixaban 2.5mgApixaban 5mgPlacebo
PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders44/84052/81154/826
BACK PAINMusculoskeletal and connective tissue disorders27/84045/81124/826
HEADACHENervous system disorders44/84041/81142/826
NASOPHARYNGITISInfections and infestations41/84031/81140/826
DIARRHOEAGastrointestinal disorders37/84024/81124/826
URINARY TRACT INFECTIONInfections and infestations28/84030/81134/826
HYPERTENSIONVascular disorders34/84019/81114/826
OEDEMA PERIPHERALGeneral disorders28/84025/81133/826
ARTHRALGIAMusculoskeletal and connective tissue disorders32/84021/81122/826
BRONCHITISInfections and infestations24/84030/81113/826

Baseline characteristics

All randomized participants regardless of whether treatment was actually received were included; intent to treat (ITT) principle.

Age Continuous
Age Continuous(years)Apixaban 2.5 mgApixaban 5 mgPlaceboTotal
Mean56.6 ± 15.356.4 ± 15.657.1 ± 15.256.7 ± 15.4
Sex: Female, Male
Sex: Female, Male(Participants)Apixaban 2.5 mgApixaban 5 mgPlaceboTotal
Female3533443611058
Male4874694681424
Region of Enrollment
Region of Enrollment(participants)Apixaban 2.5 mgApixaban 5 mgPlaceboTotal
Portugal1102
United States887596259
Philippines53311
Hong Kong43411
Spain27252678
Ukraine877788252
Chile2125
Russian Federation454946140
Israel343434102
Italy676561193
India24232471
France605550165
Australia30283189
Denmark475842147
South Africa344230106
Korea, Republic of4329
Austria1281131
United Kingdom33293092
Czech Republic434948140
Mexico22182262
Canada22171554
Argentina79622
Poland454448137
Brazil19243073
Singapore1236
Romania67720
Norway991028
Germany625560177
Index Event Classification
Index Event Classification(participants)Apixaban 2.5 mgApixaban 5 mgPlaceboTotal
Proximal DVT5445275511622
PE296286278860
08

Study locations

429 sites
  • Alabama Clinical Therapeutics, Llc
    Birmingham, Alabama 35235, United States
  • Cardiovascular Consultants, Ltd.
    Phoenix, Arizona 85032, United States
  • Robert J. Bloomberg, Md, Pc
    Tempe, Arizona 85283, United States
  • Fort Smith Lung Center
    Fort Smith, Arkansas 72901, United States
  • Beaver Medical Group
    Banning, California 92220, United States
  • Scripps Clinic/Scripps Health And Green Hospital
    La Jolla, California 92037, United States
  • Healthcare Partners Medical Group
    Los Angeles, California 90015, United States
  • Mission Internal Medical Group
    Mission Viejo, California 92691, United States
  • Desert Med Grp Inc, Dba Desert Oasis Healthcare Med Group
    Palm Springs, California 92262, United States
  • Indus Clinical Research Institute, Inc.
    Pomona, California 91767, United States
  • Kaiser Permanente Medical Center
    San Francisco, California 94118, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • Harbor Ucla Medical Center
    Torrance, California 90509, United States
  • Progressive Clinical Research
    Vista, California 92083, United States
  • Rocky Mountain Internal Medicine
    Aurora, Colorado 80012, United States
  • New West Physicians
    Golden, Colorado 80401, United States
  • Alfieri Cardiology
    Newark, Delaware 19713, United States
  • Bay Pines Va Healthcare Systems
    Bay Pines, Florida 33744, United States
  • Research Alliance, Inc.
    Clearwater, Florida 33756, United States
  • St. Francis Sleep Allergy & Lung Institute
    Clearwater, Florida 33765, United States
  • Berma Research Group
    Fort Lauderdale, Florida 33316, United States
  • Healthworx
    Hollywood, Florida 33021, United States
  • Hematology Oncology Associates
    Loxahatchee, Florida 33470, United States
  • South Miami Heart Center
    Miami, Florida 33143, United States
  • Physicians Regional Medical Group
    Naples, Florida 34119, United States
  • Richard A. Mclean M.D., P.A.
    Plantation, Florida 33317, United States
  • Tampa Clinical Research
    Tampa, Florida 33624, United States
  • Primary Care Of The Treasure Coast, Inc.
    Vero Beach, Florida 32960, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Vascular Surgical Associates, Pc
    Austell, Georgia 30106, United States
  • Atlanta Institute For Medical Research, Inc
    Decatur, Georgia 30030, United States
  • Gwinnett Biomedical Research
    Lawrenceville, Georgia 30046, United States
  • Boise Orthopedic Clinic
    Boise, Idaho 83706, United States
  • Saltzer Medical Group
    Nampa, Idaho 83686, United States
  • Infectious Disease Of Indiana Psc
    Carmel, Indiana 46032, United States
  • Office Of:Eugene C. Fletcher, Md
    New Albany, Indiana 47150, United States
  • Heartland Vascular Medicine And Surgery
    Windsor Heights, Iowa 50324, United States
  • Kentucky Lung Clinic
    Hazard, Kentucky 41701, United States
  • Owensboro Heart & Vascular
    Owensboro, Kentucky 42303, United States
  • Pen Bay Medical Center
    Rockport, Maine 04856, United States
  • Anne Arundel Health System Research Institute, Inc.
    Annapolis, Maryland 21401, United States
  • Cape Cod Research Institute
    Hyannis, Massachusetts 02601, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • Veterans Affairs Medical Center
    Kansas City, Missouri 64128, United States
  • Mercury Street Medical Group, Pllc
    Butte, Montana 59701, United States
  • Great Falls Clinic, Llp
    Great Falls, Montana 59405, United States
  • Internal Medical Associates Of Grand Island, P.C
    Grand Island, Nebraska 68803, United States
  • Creighton University Medical Center
    Omaha, Nebraska 68131, United States
  • Kaleida Health System
    Buffalo, New York 14209, United States
  • Goshen Medical Associates
    Goshen, New York 10924, United States
  • Sjh Cardiology Associates
    Liverpool, New York 13088, United States
  • Richmond University Medical Center
    Staten Island, New York 10310, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • Thomas L. Ortel, Md, Phd
    Durham, North Carolina 27710, United States
  • Valley Internal Medicine
    Fayetteville, North Carolina 28304, United States
  • Rex Healthcare
    Raleigh, North Carolina 27607, United States
  • Piedmont Healthcare/Research
    Statesville, North Carolina 28625, United States
  • Whiteville Medical Associates, P.A.
    Whiteville, North Carolina 28472, United States
  • Wilmington Medical Research
    Wilmington, North Carolina 28401, United States
  • Akron General Medical Center
    Akron, Ohio 44307, United States
  • Community Health Care, Inc.
    Canal Fulton, Ohio 44614, United States
  • Valley Medical Research
    Centerville, Ohio 45459, United States
  • Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • Remington Davis Inc.
    Columbus, Ohio 43215, United States
  • Jobst Vascular Center At The Toledo Hospital
    Toledo, Ohio 43606, United States
  • Cor Clinical Research, Llc
    Oklahoma City, Oklahoma 73103, United States
  • Pma Medical Specialists
    Phoenixville, Pennsylvania 19460, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Charleston Hematology Oncology Associates, Pa
    Charleston, South Carolina 29414, United States
  • Greenville Hospital System
    Greenville, South Carolina 29615, United States
  • Three Rivers Medical Associates, Pa
    Irmo, South Carolina 29063, United States
  • Clinical Research Authority, Llc
    Murrells Inlet, South Carolina 29576, United States
  • Palmetto Clinical Research
    Summerville, South Carolina 29485, United States
  • Holston Medical Group
    Bristol, Tennessee 37620, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Amarillo Heart Clinical Research Institute Inc.
    Amarillo, Texas 79106, United States
  • Corsicana Medical Research
    Corsicana, Texas 75110, United States
  • Ankur Doshi, Md
    Houston, Texas 77024, United States
  • Northwest Heart Center
    Tomball, Texas 77375, United States
  • Tanner Clinic
    Layton, Utah 84041, United States
  • University Of Utah Hospital
    Salt Lake City, Utah 84132, United States
  • University Of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Sentara York Clinical Research
    Norfolk, Virginia 23510, United States
  • Lake Washington Vascular, Pllc
    Bellevue, Washington 98004, United States
  • Franciscan Research Center
    Tacoma, Washington 98405, United States
  • Medical Assoicates Inc.
    Menomonee Falls, Wisconsin 53051, United States
  • Local Institution
    Capital Federal, Buenos Aires C1426ANZ, Argentina
  • Local Institution
    Ciudad Autonoma De Buenos Aire, Buenos Aires 1093 AAS, Argentina
  • Local Institution
    Ciudad Autonoma De Buenos Aire, Buenos Aires C1180AAX, Argentina
  • Local Institution
    Ciudad Autonoma De Buenos Aire, Buenos Aires C1437JCP, Argentina
  • Local Institution
    Ciudad De Buenos Aires, Buenos Aires C1034ACO, Argentina
  • Local Institution
    Ciudad De Buenos Aires, Buenos Aires C1181ACH, Argentina
  • Local Institution
    Coronel Suarez, Buenos Aires B7540GHD, Argentina
  • Local Institution
    La Plata, Buenos Aires 1900, Argentina
  • Local Institution
    La Plata, Buenos Aires B1902COI, Argentina
  • Local Institution
    Mar Del Plata, Buenos Aires 7600, Argentina
  • Local Institution
    San Martin, Buenos Aires B1650CSQ, Argentina
  • Local Institution
    Rosario, Santa Fe S2000CVB, Argentina
  • Local Institution
    Rosario, Santa Fe S2000DSV, Argentina

Showing the first 100 of 429 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Jamieson MJ, Byon W, Dettloff RW, Crawford M, Gargalovic PS, Merali SJ, Onorato J, Quintero AJ, Russ C. Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data. Am J Cardiovasc Drugs. 2022 Nov;22(6):615-631. doi: 10.1007/s40256-022-00524-x. Epub 2022 May 16. PubMed 35570249 ↗
  • Liu X, Thompson J, Phatak H, Mardekian J, Porcari A, Johnson M, Cohen AT. Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trial. Thromb Haemost. 2016 Jan;115(1):161-8. doi: 10.1160/TH15-07-0606. Epub 2015 Oct 8. PubMed 26446706 ↗
  • Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8. PubMed 23216615 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Aug 2012 and a completion of Aug 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2008
First posted
Mar 12, 2008
Start
May 2008
Primary completionActual
Aug 2012
CompletionActual
Aug 2012
Results first posted
Oct 25, 2013
Last update
Nov 25, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00633893
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Mar 12, 2008
Start date
May 2008
Primary completion
Aug 2012
Completion
Aug 2012
Results posted
Oct 25, 2013
Last update
Nov 25, 2013

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion